Procter & Gamble SEC Filings

Raman Sundar G., listed as CEO-Fabric & Home Care at Procter & Gamble Co (PG), filed a Form 4 reporting transactions dated 10/01/2025. The filing shows a disposition of 41,886.4892 shares of common stock and an indirect beneficial ownership interest of 8,436.9135 shares held by a retirement plan trustee.

The filing also reports a derivative transaction dated 10/01/2025 labeled as an acquisition: a stock option with a $153.18 exercise/conversion price tied to 68,869 underlying common shares (listed as 68,869 shares beneficially owned following the transaction). An explanatory note states this reflects an adjustment to PST through September 30, 2025. The form is signed by an attorney-in-fact on 10/02/2025.

Gary A. Coombe, identified as CEO - Grooming and an officer of Procter & Gamble Co (PG), reported transactions on 10/01/2025. He was awarded 3,373 Restricted Stock Units under the 2019 Stock and Incentive Compensation Plan, increasing his direct beneficial ownership to 38,351.145 shares. The filing also shows indirect holdings of 481.8949 shares via a retirement plan trustee and 1,295.35 shares through an International Stock Ownership & Pension Plan (Switzerland). In derivatives, Mr. Coombe acquired 46,754 stock options with an exercise price of $153.18, exercisable beginning 09/29/2028 and expiring 10/01/2035. The form was signed by Wednesday Shipp as attorney-in-fact on 10/02/2025.

Ma. Fatima Francisco, an officer at Procter & Gamble Co (PG), reported transactions dated 10/01/2025. The filing shows a disposition of 27,295.0856 shares of Common Stock and an acquisition via option exercise of 62,338 shares (stock option with exercise price $153.18), resulting in 62,338 shares held directly after the exercise. Post-transaction indirect holdings include 15,998.3673 shares held by a retirement plan trustee and 2,862.8125 shares held indirectly by spouse and plan trustees. The form includes an explanatory note that the figures reflect an adjustment to PST through September 30, 2025. The report is signed by an attorney-in-fact on 10/02/2025.

Jennifer L. Davis, listed as CEO - Health Care at Procter & Gamble (PG), reported transactions dated 10/01/2025. The Form 4 shows a disposition of 64,990.9326 shares of common stock and an indirect holding of 15,535.3029 shares held by a retirement plan trustee. The filing also reports an acquisition of 68,869 stock options at an exercise price of $153.18; those options are listed as exercisable beginning 09/29/2028 with an expiration date of 10/01/2035.

The form includes an explanatory note that the indirect amount reflects an adjustment to the participant service trust through 09/30/2025. The document is signed on behalf of Ms. Davis by an attorney-in-fact on 10/02/2025. All items reported are changes in beneficial ownership as required under Section 16.

Matthew W. Janzaruk, SVP and Chief Accounting Officer of Procter & Gamble Co (PG), reported transactions dated 10/01/2025. He exercised_stock_options to acquire 13,779 shares (stock option exercise price $153.18) and directly holds those 13,779 shares following the exercise. The Form 4 also shows a sale of 1,703.9031 shares on the same date and reports 3,293.5342 shares beneficially owned indirectly via a retirement plan trustee after an adjustment through 9/30/2025. The filing was signed by an attorney-in-fact on 10/02/2025. The report is an insider disclosure of option exercise, a small open-market sale, and an adjustment to retirement-plan holdings; it contains transaction dates, amounts, and the exercise price but no cash proceeds or reasons for the transactions.

Procter & Gamble officer Keith R. Alexandra reported changes in beneficial ownership on a Form 4 covering transactions dated 10/01/2025. The filing shows a disposition of 27,529.5056 shares of common stock and indirect holdings reported as 4,479.8913, 4,895.7069, and 2,594.244 shares held via spouse and retirement plan trustee arrangements. The filing also reports two stock option acquisitions executed on 10/01/2025: 62,338 options exercisable from 09/29/2028 through 10/01/2035 (direct) and 14,163 options with the same exercisability and expiration terms (indirect by spouse). An explanatory note states the spouse/plan amounts reflect an adjustment through 09/30/2025. The form is signed by an attorney-in-fact on 10/02/2025.

Form 144 filed for Procter & Gamble (PG): an insider has notified the SEC of a proposed sale of 2,864 shares of Common Stock, with an aggregate market value of $435,628.72, scheduled approximately for 10/02/2025 on the NYSE. The shares were originally acquired as Restricted Stock Unit awards on 10/03/2022 totaling 5,341 units. The filer also reported prior sales in the last three months: 1,000 shares sold on 08/29/2025 for $156,835.00 and 6,167 shares sold on 08/19/2025 for $969,907.52. The notice includes the standard certification that the seller is not aware of undisclosed material adverse information.

Form 144: This notice reports a proposed sale of 3,837 shares of Common Stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $583,626.89 and an approximate sale date of 10/02/2025. The securities were acquired as a Restricted Stock Unit Award from The Procter & Gamble Company on 10/03/2022 (7269 units noted). The filing also discloses a sale within the past three months: 8,596 shares sold on 08/19/2025 for gross proceeds of $1,351,925.58. The issuer's outstanding shares are listed as 2,342,371,488. The signer affirms no undisclosed material adverse information.

Form 144 filing for Procter & Gamble (PG). An insider proposes to sell 4,739 shares of Common Stock through Morgan Stanley Smith Barney on 10/02/2025, with an aggregate market value of $720,825.60. The securities were acquired as a Restricted Stock Unit award on 10/03/2022 (9,750 units originally granted). The filer previously sold 13,039 shares on 08/19/2025 for gross proceeds of $2,050,693.08. The filing includes the standard representation that the signer is not aware of undisclosed material adverse information.